Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies for $695M

Shots:

• Dragonfly Therapeutics will receive an upfront $695M with milestone and royalties on sales and Merck to get option to license exclusive worldwide IPR rights of products developed using Dragonfly’s TriNKET technology
• The agreement is focus on developing and providing immunotherapies using TriNKET technology platform to treat solid malignancies
• TriNKET technology is based on NK cell receptor, is utilized for development of novel therapeutics targeting solid tumor indications

Click here to read full press release/ article | Ref: Prnewsire | Image: Prnewsire